The MHRA has approved depemokimab as an add on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

GSK plc announced the marketing authorisation of Exdensur (depemokimab) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Exdensur is now approved in two indications: ...

Sinus infections, also known as sinusitis, can leave us feeling miserable with symptoms like nasal congestion, facial pain ...

GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines ...

UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...

Angela Read thought she had a sinus infection, soon she discovered her condition was much more serious. She's grateful to the ...

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...

Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant ...

The 2025 AAO‐HNSF adult sinusitis guideline, an update of the 2015 guideline, offers evidence-based recommendations on rhinosinusitis management.

Denmark: A new systematic review and meta-analysis has shed light on how effectively biologic therapies can help restore the ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved pharma major GSK’s Exdensur (depemokimab), the first twice-yearly biological medicine for use as an add-on treatment for ...

As with any medicine, the MHRA will keep the safety and effectiveness of depemokimab under close review. The Medicines and Healthcare products ...